abstract |
The present invention provides a multimeric scaffold based on the tenascin-3 FnIII domain that specifically binds to TRAIL receptor 2 (TRAIL R2), a cell membrane receptor involved in apoptosis. The present invention further provides engineered variants that exhibit increased affinity, increased stability, and reduced immunogenicity for the target. Furthermore, the present invention relates to engineered multivalent scaffolds as prophylactic, diagnostic or therapeutic agents, and the use of such scaffolds for diseases caused by cells expressing TRAIL R2, in particular for therapeutic use against cancer. |